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Abstract
Purpose Current clinical imaging of PSMA-positive prostate
cancer by positron emission tomography (PET) mainly fea-
tures 68Ga-labeled tracers, notably [68Ga]Ga-PSMA-HBED-
CC. The longer half-life of fluorine-18 offers significant ad-
vantages over Ga-68, clinically and logistically. We aimed to
develop high-affinity PSMA inhibitors labeled with fluorine-
18 as alternative tracers for prostate cancer.
Methods Six triazolylphenyl ureas and their alkyne precursors
were synthesized from the Glu-urea-Lys PSMA binding moi-
ety. PSMA affinity was determined in a competitive binding
assay using LNCaP cells. The [18F]triazoles were isolated fol-
lowing a Cu(I)-catalyzed click reaction between the alkynes
and [18F]fluoroethylazide. The 18F-labeled compounds were
evaluated in nude mice bearing LNCaP tumors and compared
to [68Ga]Ga-PSMA-HBED-CC and [18F]DCFPyL.
Biodistribution studies of the two tracers with the highest
imaged-derived tumor uptake and highest PSMA affinity were
undertaken at 1 h, 2 h and 4 h post-injection (p.i.), and co-
administration of PMPA was used to determine whether up-
take was PSMA-specific.
Results F-18-labeled triazolylphenyl ureas were preparedwith
a decay-corrected RCYof 20–40%, >98 % radiochemical and
chemical purity, and specific activity of up to 391 GBq/μmol.
PSMA binding (IC50) ranged from 3–36 nM. The position of
the triazole influenced tumor uptake (3 > 4 > 2), and direct
conjugation of the triazole with the phenylurea moiety was
preferred to insertion of a spacer group. Image-derived tumor
uptake ranged from 6–14 %ID/g at 2 h p.i., the time of max-
imum tumor uptake; uptake of [68Ga]Ga-PSMA-HBED-CC
and [18F]DCFPyL was 5–6 %ID/g at 1–3 h p.i., the time of
maximum tumor uptake. Biodistribution studies of the two
most promising compounds gave maximum tumor uptakes
of 10.9 ± 1.0 % and 14.3 ± 2.5 %ID/g, respectively, as com-
pared to 6.27 ± 1.44 %ID/g for [68Ga]Ga-PSMA-HBED-CC.
Conclusions Six [18F]triazolylphenyl ureas were prepared in
good radiochemical yield. Compounds showed PSMA-
specific uptake in LNCaP tumors as high as 14 % ID/g, more
than a 2-fold increase over [68Ga]Ga-PSMA-HBED-CC. The
facile and high-yielding radiosynthesis of these 18F-labeled
triazoles as well as their promising in vitro and in vivo char-
acteristics make them worthy of clinical development for PET
imaging of prostate cancer.
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Introduction
Prostate cancer is the second most prevalent cancer among
men, with more than 1.1 million diagnoses in 2012 [1] and
more than 292,000 deaths due to prostate cancer reported
worldwide in 2013 [2]. The disease burden continues to
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grow—157,000 deaths were reported in 1990 [2]—and it is
estimated that more than 180,000 men will be newly diag-
nosed with prostate cancer in the United States in 2016, and
that more than 26,000 deaths due to the disease will be regis-
tered [3]. When detected early and the disease is confined to
the prostate gland and regional lymph nodes, the 5-year sur-
vival rate is nearly 100 %, but the survival rate drops below
30 % when the disease is metastatic [4]. Early diagnosis can
significantly improve patient prognosis, while sensitive and
specific localization of the disease is an important feature in
the diagnosis and staging of the disease. Accurate staging is
critical for appropriate patient management [5].
Prostate-specific membrane antigen (PSMA; also known
as glutamate carboxypeptidase II) is significantly
overexpressed in prostate cancer primary tumors and many
metastatic lesions, while expression in healthy prostate and
other tissue is limited [6]. Several other characteristics com-
bine to make PSMA an ideal target for molecular diagnostics
and therapeutics for prostate cancer: (1) it is overexpressed at
all stages of the disease; (2) expression typically correlates
with tumor grade, disease aggressiveness, metastasis and bio-
chemical recurrence; (3) it is a transmembrane protein with an
extracellular ligand-binding domain; and (4) the bound
ligand-protein complex is internalized via receptor-mediated
clathrin-dependent endocytosis [7, 8]. The potential utility of
PSMA as a target for diagnostic imaging and therapy was
demonstrated with the radiolabeled monoclonal antibody
J591 [9], using In-111 or Zr-89 for imaging and Y-90 or Lu-
177 for therapy, however the pharmacokinetics of the anti-
body make it unsuitable for diagnostic imaging with short-
lived radionuclides [10].
A number of low molecular weight, urea-based small
molecules have been described as single photon emission
computed tomography (SPECT) or positron emission to-
mography (PET) imaging agents for prostate cancer, and
several of them are undergoing clinical investigation in
humans (structures can be found in Fig. S1 of the
Supplementary Materials). Currently, seven such molecules
are in Phase I/II clinical trials in the United States and/or
Europe: (i) radioiodinated MIP-1095 (I-123 for SPECT/CT
and I-124 for PET/CT) and MIP-1072 (I-123 for SPECT/
CT), developed by Molecular Insight Pharmaceuticals, Inc.,
(ii) 99mTc-MIP-1404 and 99mTc-MIP-1405, two further
SPECT imaging agents emerging from the Molecular Insight
Pharmaceuticals platform, (iii) [68Ga]Ga-PSMA-HBED-CC
(also known as [68Ga]PSMA-11 and [68Ga]DKFZ-PSMA-
11) for PET/CT, and (iv) [18F]DCFBC and its next-
generation derivative [18F]DCFPyL for PET/CT [11, 12].
Newly introduced compounds to undergo first-in-human eval-
uation include 68Ga-DKFZ-617, developed to be a theranostic
ligand and evaluated in a therapeutic context as 177Lu-DKFZ-
617 [13], and the structurally related 68Ga-CHX-A^-DTPA
[14].
The greater sensitivity and higher spatial resolution of PET
relative to SPECT has made this technique the preferred im-
aging platform in a number of clinical environments [15, 16].
Among the positron-emitting isotopes currently incorporated
into PSMA-targeting ligands, fluorine-18 and gallium-68 are
preferred to iodine-124 because of their higher efficiency of
positron emission (97 % and 89 % vs. 23 %, respectively) and
shorter half-lives. Furthermore, iodine-124 scans require com-
plex reconstruction algorithms to minimize the signal-to-noise
ratio, which, in combination with the long half-life of iodine-
124 (t1/2 = 4.18 d) and the undesired emission of beta particles,
is often a poor match for the pharmacokinetics of small mol-
ecules [17]. In addition, gallium-68 is currently produced from
a 68Ge/68Ga generator, enabling its use in single-batch synthe-
ses in radiopharmacies independent of access to a cyclotron,
and chelation of gallium-68 is both clean and rapid under
conditions that are compatible with most small molecules
and peptides. These considerations have contributed to the
emergence of [68Ga]Ga-PSMA-HBED-CC as themost widely
used radiotracer currently in clinical development [18].
Fluorine-18 presents a number of practical advantages com-
pared to gallium-68, including: (i) a longer half-life [t1/2(
18F) =
109.8 min vs. t1/2(
68Ga) = 67.7 min], which permits multiple
step radiosyntheses and allows a longer time for background
signals to clear before imaging is performed, (ii) large-scale
cyclotron production that allows multiple patient doses to be
produced from a single synthesis, and (iii) chemical character-
istics, such as a similar atomic radius to hydrogen, that allow
diverse types of ligands to be prepared. On this basis, the de-
velopment of PSMA-targeting ligands labeled with fluorine-18
has emerged recently as a goal of great interest. [18F]DCFBC is
based on a Glu-urea-Cys pharmacophore modified with a
4-[18F]fluorobenzyl group, and was reported to show good up-
take in PSMA+ xenograft tumors [19]. In humans, however, it
has shown limited clearance from soft tissue, resulting in a
decreased tumor-to-background ratio and poor visualization of
small lesions [20, 21]. To address the slow clearance, the
second-generation [18F]fluoropyridine-modified Glu-urea-Lys
analogue [18F]DCFPyL was developed [22]. Despite more
promising pharmacokinetics, fast tumor washout is evident as
early as 1 h post-injection (p.i.) and accumulation of radioac-
tivity in evacuated bladders is considerable [22]. In addition,
[18F]DCFPyL suffers from poor radiochemical yields (in the
range 5–12 % decay-corrected [23, 24], although recently an
improved synthesis by direct fluorination has been reported to
increase yield to greater than 20 % [25].
In an effort to address the aforementioned challenges in the
development of fluorine-18-PSMA ligands of high specificity
and affinity, we describe the synthesis and preliminary
structure-activity relationship (SAR) studies of two new clas-
ses of [18F]fluoroethyltriazolylphenyl urea-based PSMA li-
gands, afforded by click chemistry in high radiochemical yield
(20–40 %), excellent radiochemical purity (>99 %) and high
648 Eur J Nucl Med Mol Imaging (2017) 44:647–661
specific activity (182–391 GBq/μmol) from starting activities
of less than 7.4 GBq (200 mCi). Each of these ligands shows
substantial tumor uptake in nude mice bearing LNCaP xeno-
grafts using μPET/CT. The two most promising ligands, RPS-
040 and RPS-041, show excellent PSMA imaging character-
istics based on their high specificity for PSMA, high tumor
uptake and prolonged tumor retention, rapid clearance from
non-target tissues and resulting high tumor-to-background ra-
tios. They also show superior pharmacokinetics when com-
pared to [68Ga]Ga-PSMA-HBED-CC in mice, thereby
warranting development as clinical PET imaging agents for
prostate cancer.
Materials and methods
Synthesis of alkyne precursors
The alkyne precursors were synthesized by one of two routes,
described in Fig. 1. In route A, the phenylurea moiety was
synthesized by coupling an alkyne-substituted aniline with
the p ro t e c t ed Glu -u r ea -Lys g roup [26 ] v i a 2 -
carbonyldiimidazole, with acid-catalyzed deprotection giving
the alkyne precursor. In route B, the aniline was converted to
an isocyanate via triphosgene and then treated with the
deprotected Glu-urea-Lys group. This route avoided acid-
catalyzed deprotection of acid-sensitive compounds. Full ex-
perimental details can be found in the Supplementary
Materials.
Synthesis of fluorinated triazoles
The reference triazoles were synthesized from 2-
fluoroethylazide [27] and the corresponding alkyne as de-
scribed in Fig. 2. Full experimental details can be found in
the Supplementary Materials.
Synthesis of 2-azidoethyltosylate
The 2-azidoethyltosylate (15) synthon for 18F-fluorination
(Fig. 3) was synthesized in two steps from 2-bromoethanol
[28]. A nucleophilic substitution reaction involving sodium
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Fig. 1 Synthesis of phenylureas derivatized with alkynes as precursors for click chemistry
Fig. 2 Synthesis of two classes of phenylureas derivatized with triazoles. Series one contains RPS-039, RPS-043 and RPS-038. Series two contains
RPS-042, RPS-040 and RPS-041
Fig. 3 Two-step radiosynthesis of six phenylureas by click chemistry
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azide generated 2-azidoethanol, with tosylation by p-
toluenesulfonyl chloride providing the precursor for




All solvents and reagents were purchased from Sigma-Aldrich
and were of reagent grade quality unless otherwise indicated.
All reactions were carried out in oven-dried glassware.
Fluorine-18 was obtained by irradiation of H2
18O (Rotem
Industries) via the 18O(p,n)18F transformation using a TR19
cyclotron (Advanced Cyclotron Systems, Inc.). End-of-
bombardment activity was typically 5.55-9.25 GBq (150–
250 mCi). Analytical and semi-preparative high-performance
liquid chromatography (HPLC) were performed on a dual
pump Varian high-performance liquid chromatography
(Agilent Technologies) fitted with a dual ultraviolet-visible
light (UV–vis) detector and an NaI(Tl) detector (Bioscan).
Solvent A was 0.01 % trifluoroacetic acid (TFA) in H2O and
solvent B was 0.01 % TFA in 90:10 v/v MeCN:H2O. Semi-
prep HPLC was performed on a Bondapak C18 7.8 x 300-
mm, 125-Å column (Waters) while analytical HPLC was per-
formed on a Symmetry C18 4.6 x 50-mm, 100-Å column
(Waters). The UV absorption spectrum was monitored at
220 nm and 280 nm. Semi-prep HPLC was performed using
an isocratic solvent mixture of 15 % B at a flow rate of 4 mL/
min. Analytical HPLC was generally performed at a flow rate
of 2 ml/min using the following gradient; 0%B 0–1 min., 0–
100%B 1–8 mins., 100–0%B 8–10 mins.
All radiochemical yields were corrected to the [18F]fluoride
activity measured at start-of-synthesis. The reaction condi-
tions reported represent the highest yields obtained usingman-
ual radiosyntheses. The radiosynthesis of [68Ga]Ga-PSMA-
HBED-CC [29] and [18F]DCFPyL [22] were performed ac-
cording to previously reported methods and are described in
the supporting information.
Radiosynthesis of the 18F-RPS series
No-carrier-added [18F]fluoride was trapped on a pre-activated
Sep-Pak QMA cartridge (Waters) and eluted with 1 mL of an
80 % v/v MeCN/H2O solution containing 2.7 mg K2CO3 and
4 mg Kryptofix-222. The solution was dried azeotropically with
MeCN (2 x 0.5 mL) at 100 °C in 10 min. To the dried F-18 was
added a solution of 2-azidoethyltosylate (15; 6 mg) in MeCN
(300 μL). The resulting solution was stirred at 80 °C for 10 min
to yield 2-[18F]fluoroethylazide. The 2-[18F]fluoroethylazide was
purified by distillation by heating the vial at 130 °C and trapping
the 2-[18F]fluoroethylazide in a vial containing 100 μL
dimethylformamide (DMF) cooled to 0 °C.
A pre-mixed solution of 0.5 M CuSO4 (50 μL) and 1.5 M
sodium ascorbate (50 μL) in DMF (100 μL) was added to the
vial containing the 2-[18F]fluoroethylazide solution followed
by 1 mg of alkyne precursor (6–8; 10–12) in dimethyl sulfox-
ide (DMSO; 100–150 μL). The reaction was stirred at 100 °C
for 20 min. It was then cooled to room temperature, diluted
with 2 mL H2O and filtered through a 0.45-μm nylon syringe
filter (Cole-Parmer). The filter was washed with 1 mL H2O,
which was added to the filtrate. The filtrate was purified by
semi-prep reverse-phase HPLC (4 mL/min; 0–100 % B;
30 min), and the peak corresponding to 18F-labeled triazole
was collected, diluted with H2O and passed through a pre-
activated Oasis™ solid-phase extraction cartridge (Waters).
The retained activity was eluted with ethanol (EtOH) and di-
luted with 0.9 % NaCl solution until the concentration of
ethanol was less than 5 % v/v and the radioactivity concentra-
tion was a minimum of 74 MBq/mL. The synthesis, purifica-
tion and final formulation were achieved in 105 min from
start-of-synthesis. An optimized isocratic HPLC purification
method (4 mL/min; 15 % B; 30 min) was used to isolate
[18F]RPS-040 and [18F]RPS-041 in 20–40 % decay-
corrected radiochemical yield, greater than 99 % radiochemi-
cal purity and a specific activity of up to 391 GBq/μmol.
Cell culture
The human prostate cancer cell line, LNCaP, was obtained
from the American Type Culture Collection. Cell culture sup-
plies were from Invitrogen unless otherwise noted. LNCaP
cells were maintained in RPMI-1640 medium supplemented
with 10 % fetal bovine serum (Hyclone), 4 mM L-glutamine,
1 mM sodium pyruvate, 10 mMN-2-hydroxyethylpiperazine-
N-2-ethanesulfonic acid (HEPES), 2.5 mg/mLD-glucose, and
50 μg/mL gentamicin in a humidified incubator at 37 °C/5 %
CO2. Cells were removed from flasks for passage or for trans-
fer to 12-well assay plates by incubating them with 0.25 %
trypsin/ethylenediaminetetraacetic acid (EDTA).
In vitro determination of IC50
The 50 % inhibition concentrations (IC50 ) values of the non-
radioactive fluorine-containing ligands were determined by




7,12,16,18-tetracarboxylic acid technetium tricarbonyl com-
plex; 99mTc-MIP-1427) for binding to PSMA on LNCaP cells,
according to methods previously described [30]. The LNCaP
cells were plated 48 hours prior to the experiment to achieve a
density of approximately 5 x 105 cells/well (in triplicate) in
RPMI-1640medium supplemented with 0.25% bovine serum
Eur J Nucl Med Mol Imaging (2017) 44:647–661 651
albumin prior to performing the assay. LNCaP cells were in-
cubated for 1 hour with 1 nM 99mTc-MIP-1427 in serum-free
RPMI-1640 medium in the presence of 1–10,000 nM test
compounds. Radioactive incubation media was then removed
by pipette and the cells were washed twice using 1 mL of ice-
cold HEPES buffer. Cells were harvested from the plates and
transferred to tubes for radioactive counting using a Packard
Cobra II gamma counter. IC50 values were determined by non-
linear regression using GraphPad Prism software.
Inoculation of mice with xenografts
All animal studies were approved by the Institutional Animal
Care and Use Committee of Weill Cornell Medicine and were
undertaken in accordance with the guidelines set forth by the
USPHS Policy on Humane Care and Use of Laboratory
Animals. Animals were housed under standard conditions in
approved facilities with 12-h light/dark cycles. Food and wa-
ter was provided ad libitum throughout the course of the stud-
ies. Male inbred athymic nu/nu mice were purchased from
The Jackson Laboratory. For inoculation inmice, LNCaP cells
were suspended at 4 x 107 cells/mL in a 1:1 mixture of
PBS:Matrigel (BD Biosciences). Each mouse was injected
in the left flank with 0.25 mL of the cell suspension. The mice
were imaged when the tumors reached approximately 200–
400mm3, while biodistributions were conducted when tumors
were in the range 100–400 mm3.
Imaging
LNCaP xenograft tumor-bearing mice (two per compound)
were injected intravenously via the tail vein as a bolus injec-
tion of 7.03–7.77MBq (190–210 μCi) of the tracer ([18F]RPS
series), 5.5–6.5 MBq (150–175 μCi) [18F]DCFPyL or
5.5 MBq (150 μCi) [68Ga]Ga-PSMA-HBED-CC. Specific
activity was greater than 190 GBq/μmol. The mice were im-
aged by μPET/CT (Inveon™; Siemens Medical Solutions,
Inc.) at 1 h, 2 h, 4 h and 6 h p.i. ([18F]fluorinated compounds)
or 1 h and 3 h p.i. ([68Ga]Ga-PSMA-HBED-CC). Total acqui-
sition time was thirty minutes, and a CT scan was obtained
either immediately before or immediately after the acquisition
for both anatomical co-registration and attenuation correction.
The data were reconstructed using the commercial Inveon™
software supplied by the vendor. Tumor uptake was estimated
by drawing a region of interest (ROI).
Biodistribution
LNCaP xenograft tumor-bearing mice (n = 5 per time point)
were injected via the tail vein with a bolus injection of
370 kBq (10 μCi) of either [18F]RPS-040 or [18F]RPS-041.
The specific activity of the compounds was 341 GBq/μmol
and 391 GBq/μmol, respectively. The mice were euthanized
by asphyxiation under isofluorane at 1 h, 2 h and 4 h p.i. An
additional set of mice (n = 5) was co-administered [18F]RPS-
040 (370 kBq; 10 μCi) and 2-PMPA (approx. 250 μg; 10 mg/
kg) and sacrificed at 1 h p.i. to determine the uptake specific-
ity. A full biodistribution study was conducted on all mice,
and tissues were excised, weighed and counted in an automat-
ed γ-counter. Tissue time-activity values were expressed as
percentage injected dose per gram of tissue (%ID/g).
Statistical comparisons were performed using the standard
Student’s t test for a 95 % confidence interval.
Results
Synthesis and radiosynthesis
The synthetic schema of the six 18F-fluorinated PSMA inhib-
itors [18/19F]RPS-038 to [18/19F]RPS-043 is given in Figs. 1–3.
Full experimental details, including a description of unexpect-
ed acid-catalyzed degradation of certain alkyne precursors that
necessitated an alternative synthetic route, are available in the
Supplementary Information.
The two classes of alkyne precursors were synthesized
via different routes due to the instability of some of the
alkyne precursors towards the acidic deprotection of the
tert-butyl esters. The 2- and 4-((propenyloxy)phenyl)urea (6,
8) and 3-((ethynyl)phenyl)urea (7) precursors were largely
stable to acidic deprotection and so were synthesized in three
steps from the protected Glu-urea-Lys (1) intermediate. Some
degradation of the 3-((ethynyl)phenyl)urea was observed dur-
ing deprotection, but the major product was the desired al-
kyne. However, the 2- and 4-((ethynyl)phenyl)ureas (10, 12)
and the 3-((propenyloxy)phenyl)urea (11) required conversion
to their corresponding isocyanates with triphosgene, and the
crude reaction products were then treated with the free acid
form of the Glu-urea-Lys (9) pharmacophore (Fig. 1). The
yields of the 3-substituted phenylureas (6.6–20.0 % from
(1)) were relatively poor using either synthetic route, while
the 2-substituted phenylureas (27.3–28.2 %) and 4-
substituted phenylureas (26.5–33.4 %) were synthesized in
greater yields from the same starting point.
The cold 19F containing ligands RPS-038–RPS-043
were synthesized by a Cu(I)-catalyzed click reaction with
2-fluoroethylazide (16), prepared in situ from 2-
fluoroethyltosylate (13) and sodium azide (Fig. 2).
Following semi-prep HPLC purification, the triazoles
RPS-038, RPS-040, RPS-042 and RPS-043 were isolated
in 60–82 % yield. The yields of RPS-041 (50 %) and
RPS-039 (34 %) were somewhat lower than expected,
likely due to potential contamination of the alkyne
starting material with inseparable impurities.
The radiosynthetic schema describing the preparation of the
18F-containing triazoles from their alkyne precursors (6–8, 10–
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12) is provided in Fig. 3. 2-Azidoethyltosylate (15) was synthe-
sized in two steps from 2-bromoethanol and added as a solution
in MeCN to azeotropically dried [18F]fluoride-K2CO3-kryptofix.
Incorporation of [18F]fluoride was greater than 90 % (n = 12) by
radio-HPLC after 10 minutes at 80 °C. Following distillation at
130 °C, 50.1 ± 11.7 % of the 2-[18F]fluoroethylazide ([18F](16))
was isolated in greater than 95 % radiochemical purity. Up to
40% of the 2-[18F]fluoroethylazide remained in the reaction vial,
but the addition of small volumes of MeCN to increase recovery
was found to have a detrimental effect on the subsequent click
reaction.
The click reaction was carried out in mixtures of
DMSO/MeCN and yields were highly sensitive to reac-
tion volume and MeCN content. Conversion to the tri-
azole was 50.5 ± 6.7 % (n = 8; as measured by radio-
HPLC) when undertaken at 100 °C for 20 min and when
the total reaction volume was 600 μL and the MeCN
content was 25 %. When MeCN content increased up to
50 %, conversion dropped below 25 %, while an increase
in total reaction volume to 1050 μL with 25 % MeCN
content dropped conversion to 30–35 %.
High radiochemical purity (>95 %) preparation of the
[18F]fluorinated triazole was accomplished after solid-
phase C18 extraction, which retained approximately
65 % of the labeled triazole and less than 5 % of the
unreacted 2-[18F]fluoroethylazide. However, the specific
activity of this preparation was low due to contamination
with the unreacted alkyne. Therefore, purification by
semi-prep HPLC, following filtration of the diluted reac-
tion mixture through a 0.45-μm filter to remove solid
residues, was used in preference to solid-phase extraction.
Recovery of the [18F]fluorinated triazole following filtra-
tion and HPLC purification was 76.0 ± 6.9 %. Following
this procedure, the [18F]fluorinated ligands were isolated
in 20–40 % radiochemical yield (decay-corrected to start-
of-synthesis) and a specific activity of 182–391 GBq/
μmol. Optimization and automation of the radiosynthesis
and purification are ongoing.
In vitro evaluation
The affinity for PSMA was determined in a competitive
binding assay using LNCaP cells, and the IC50s of the six
compounds ranged from 3.2–36.5 nM (Table 1). In the
same LNCaP-based assay, MIP-1095 was determined to
have an IC50 of 0.3 nM while DCFPyL, a fluorinated
PSMA inhibitor [22] currently undergoing first-in-human
trials in the United States [24] and Europe [23] had an
IC50 of 22.8 nM (Table 1). [
68Ga]Ga-PSMA-HBED-CC
has been reported to have an IC50 of approximately 24
nM for PSMA in a competitive binding assay using
LNCaP cells [14, 31].
In vivo evaluation
The six compounds were assessed in a mouse model of pros-
tate cancer by μPET/CT imaging at 1 h, 2 h, 4 h and 6 h p.i.
Each of the compounds showed good tumor uptake by 1 h,
with uptake peaking at 2 h and maintaining a steady value up
to 4 h (Fig. 4). No significant washout was observed by 6 h. In
contrast, signals in other tissues such as the kidneys and liver
began to decrease after 1 h, leading to high-contrast images by
2 h p.i. Excretion was predominantly via the urine as evi-
denced by the rapid accumulation of activity in the bladder
of these mice. Urine was not collected.
The maximum tumor uptake (t = 2 h) for the compounds in
series one was estimated from the μPET/CT images to range
from 5.89 ± 0.27%ID/g to 9.04 ± 1.88%ID/g and with uptake
of [18F]RPS-043 > [18F]RPS-038 > [18F]RPS-039 (Table 1).
Uptake did not directly correlate with the IC50 determined in
LNCaP cells, as RPS-039 had the highest affinity for PSMA
(14 nM) in series one, but the lowest tumor uptake (5.87 ±
0.27 %ID/g). Compounds in series two showed greater tumor
uptake and higher contrast than their series one structural
counterparts. Maximum tumor uptake (t = 2 h) was derived
from the image and calculated to range from 10.06 ± 1.33
%ID/g to 14.30 ± 0.67 %ID/g and in the order [18F]RPS-
040 > [18F]RPS-041 > [18F]RPS-042 (Table 1). It was again
the case that the highest affinity compound ([18F]RPS-041;
IC50 = 3.2 nM) did not have the highest tumor uptake.
The major route of clearance appeared to be via the
kidneys, with the exception of RPS-039 and RPS-042,
which showed clearance via the hepatobiliary pathway
in addition to renal clearance. These two compounds
share substitution at the 2-position of the phenylurea as
a structural feature. While [18F]RPS-039 was the most
potent series one compound in the in vitro binding assay,
both [18F]RPS-039 and [18F]RPS-042 had the lowest tu-
mor uptake and lowest image contrast of their respective
series.
[18F]RPS-040 and [18F]RPS-041, which had both the
highest image-derived tumor uptake (14.30 %ID/g and
12.51 %ID/g, respectively) and greatest tumor/background
contrast in the μPET/CT images, were evaluated further by
biodistribution studies in LNCaP xenograft tumor-bearing
mice.
The imaging findings were corroborated in biodistribution
studies where maximum tumor uptake was observed at 2 h p.i.
for both ligands (Figs. 5 and 6), with [18F]RPS-040 reaching
14.30 ± 2.49 %ID/g (n = 5) and [18F]RPS-041 peaking at
10.86 ± 1.03 %ID/g (n = 5). At this time point, uptake is also
observed in the kidneys (60.94 ± 8.06 and 23.93 ± 5.45), the
spleen (3.23 ± 1.26 and 1.13 ± 0.47) and the liver (4.72 ± 0.93
and 2.51 ± 0.21). Tumor-to-background ratios are plotted in
Fig. 7. The ratios favor [18F]RPS-041, which has a slightly lower
tumor uptake than [18F]RPS-040 at all time points, but a
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considerably lower background signal. At 2 h p.i., contrast with
[18F]RPS-041 is two-fold greater than with [18F]RPS-040.
To demonstrate that uptake was PSMA-mediated, five
mice were co-injected with [18F]RPS-040 and 2-
Table 1 Structure and in vitro affinities for PSMA and HSA of PSMA-binding ligands
a = See Ref [26]
b = See Ref [14]
c = Image derived calculation of tumor uptake
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phosphonomethylpentanedioic acid (2-PMPA), a potent
PSMA inhibitor [32], and sacrificed at 1 h p.i. At this time
point, tumor uptake decreased from 12.69 ± 1.56 %ID/g (n =
5) in the unblocked set of mice to 1.75 ± 0.15 %ID/g (n = 5) in
the set co-administered with 2-PMPA. Similar blocking was
observed in the spleen (4.97 ± 1.55 %ID/g vs 0.32 ± 0.05
%ID/g) and kidneys (74.24 ± 10.71 %ID/g vs 5.95 ± 1.65
%ID/g; Fig. 5), two other organs known to express PSMA
in nude mice [33].
Comparison to [68Ga]Ga-PSMA-HBED-CC
A comparison of μPET/CT images of [18F]RPS-040 and
[18F]RPS-041 with [68Ga]Ga-PSMA-HBED-CC shows
significantly higher kidney uptake (p < 0.0002) and low-
er tumor uptake (p < 0.0008) in the gallium-68 tracer at
1 h p.i. (Fig. 8). No uptake in the liver or intestine is
evident in the [68Ga]Ga-PSMA-HBED-CC.
These observations are reflected in the findings of ex vivo
biodistributions. A recently reported study of [68Ga]Ga-
PSMA-HBED-CC demonstrated tumor uptake to be 5.81
± 1.67 %ID/g at 1 h p.i. and 6.27 ± 1.44 %ID/g at 3 h p.i.
[34]. At the time of maximum tumor uptake, therefore,
[18F]RPS-040 shows more than two-fold greater uptake than
[68Ga]Ga-PSMA-HBED-CC, while [18F]RPS-041 is nearly
two-fold greater. In comparison to both [18F]RPS-040 and
[18F]RPS-041, activity in the blood was higher, while activity
in the kidney (314.44 ± 90.61 at 1 h; 207.97 ± 58.38 at 3 h)
and the spleen (31.73 ± 14.09 at 1 h; 13.85 ± 3.53 at 3 h) was
significantly higher (p < 0.0002 and p < 0.002, respectively).
These pharmacokinetics result in higher tumor uptake and
enhanced tumor-to-background ratios for [18F]RPS-040 and
[18F]RPS-041 relative to [68Ga]Ga-PSMA-HBED-CC
(Fig. 9).
At 1 h p.i., the tumor-to-blood ratio for [18F]RPS-041 and
[18F]RPS-040 are more than two-fold and three-fold greater, re-
spectively, than for [68Ga]Ga-PSMA-HBED-CC, and these ra-
tios continue to grow with time. The tumor-to-kidney ratio is
even more striking, as [18F]RPS-040 and [18F]RPS-041
Fig. 4 Micro-PET/CT images of
a series of [18F]fluorinated PSMA
ligands in LNCaP xenograft
tumor-bearing mice. Mice (n = 2
per time point) were imaged at
1 h, 2 h, 4 h and 6 h p.i. All
images are scaled to correct for
decay and the highest tumor
uptake image (RPS-040; 2 h p.i)
is used as the reference for setting
the intensity scale
Fig. 5 Biodistribution of [18F]RPS-040 in LNCaP xenograft tumor-
bearing mice. Mice (n = 5 per time point) were sacrificed at 1 h (1 h
p.i.), 2 h (2 h p.i.) and 4 h (4 h p.i.) p.i. To determine specificity for
PSMA, 2-PMPA was co-administered and the mice were sacrificed at
1 h p.i. (n = 5; 1 h p.i. blocked)
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demonstrate ten- and twelve-fold greater contrast, respectively;
once again, the relative contrast increases with time.
Discussion
A prosthetic group strategy was envisioned for the synthesis
and radiosynthesis of the six PSMA inhibitors. By this ap-
proach, it was possible to overcome the interaction between
fluoride and the urea protons [35] which contributes to low
yield and high variability in the direct fluorination of urea-
based imaging probes. Copper(I)-catalyzed click reactions
have proven to be useful in radiochemistry due to their rapid
kinetics and broad functional group tolerance, which allow
labeling under mild conditions and in the absence of
protecting groups as well as reduced reaction times [36–38].
2-[18F]Fluoroethylazide has been reported to be synthesized
in good radiochemical yields and to react with small mole-
cules and peptides [27, 39–41]. It has three principal advan-
tages in the context of radiochemical synthesis: 1) it is the
smallest azide that can be radiofluorinated, and the size of
the resulting [18F]fluoroethyltriazole permits it to be incorpo-
rated into small molecules without necessarily disrupting ac-
tivity [39]; 2) it can be purified by distillation, leading to high
specific activity productions [27, 39]; and 3) when Cu(I) is in
stoichiometric excess, as it typically is for reactions on a ra-
diochemical scale, the click reaction is second-order with re-
spect to the alkyne [39, 42, 43].
The application of the 2-[18F]fluoroethylazide/Cu(I)-cata-
lyzed click chemistry methodology to the radiosynthesis of
small PSMA-binding molecules was demonstrated to be a
straightforward and reproducible route to high-affinity ligands
synthesized in good radiochemical yield. The synthesis of
2-[18F]fluoroethylazide was found to be highly efficient and
reproducible, though substantial losses were observed during
distillation. Although addition of small aliquots ofMeCN to the
reaction vial increased the recovery of 2-[18F]fluoroethylazide
after distillation, the additional volume of MeCN was found to
suppress the yield of the click reaction.
Optimization of the click reaction is ongoing, but early
experiences have highlighted the sensitivity of the reaction
to total reaction volume and the composition of reaction sol-
vents. Conversion to the [18F]fluorinated triazoles was better
in smaller reaction volumes; this is likely to be the conse-
quence of higher reagent concentration. However, in reactions
with similar volumes, those that had a higher MeCN content
gave poorer triazole yields. This is consistent with reports of
the percentage of DMF in the reaction mixture playing an
important role in maintaining high levels of Cu(I) [39]. The
similar boiling points of MeCN and 2-[18F]fluoroethylazide
prevent concentration of the distillate, limiting the minimum
volume of MeCN that can be used. Therefore, improvements
in the yield of the click reaction will likely arise from increas-
ing the concentration of alkyne and/or the CuSO4/sodium
ascorbate mixture.
Recently, a potential [18F]fluorinated PSMA ligand synthe-
sized by a click approach using 2-([18F]fluorophenyl)acetylene
as a synthon has been reported [41]. The biological characteris-
tics and pharmacokinetics of the ligand have yet to be
established. Although the decay-corrected radiochemical yield
was reported to be 30 %, the synthon is synthesized in 3 steps,
and this limits even further the potential for automation of the
process. Therefore, the use of 2-[18F]fluoroethylazide as the pros-
thetic group for radiofluorination appears to be a more promising
route to a [18F]fluorinated PSMA ligand produced in quantities
appropriate for clinical use.
The potent PSMA inhibitor MIP-1095 was used as a struc-
tural lead due to its high affinity for PSMA and high tumor
uptake in both LNCaP xenograft tumor-bearing mice [44] and
in humans [45]. The rigidity of the phenylurea is credited with
improved potency relative to the amide analogue MIP-1072
[46] and was, therefore, a key feature retained in the structure
of the newly described ligands. The ethynyl moiety has been
described as a potential bioisosphere of iodine [47], and the
subsequent 1,2,3-triazole has been proposed to be a
bioisosphere of amide bonds [48], suggesting that the struc-
tural modificationsmight not have a severely adverse effect on
affinity for PSMA. Furthermore, the fluoroethyl moiety might
project more deeply into the S1 accessory hydrophobic pocket
identified in crystal structures of glutamate carboxypeptidase
II with bound ligands [49]. While the six triazolyl urea com-
pounds ultimately displayed lower affinities for PSMA than
MIP-1095, the imaging and biodistribution studies demon-
strated that of the promising pharmacokinetics of the structural
lead were retained.
The SAR studies highlight two clear trends in tumor up-
take. Compounds in series 2 had greater uptake than their
counterparts in series 1 (Table 1), indicating a preference for
Fig. 6 Biodistribution of [18F]RPS-041 in LNCaP xenograft tumor-
bearing mice. Mice (n = 5 per time point) were sacrificed at 1 h (1 h
p.i.), 2 h (2 h p.i.) and 4 h (4 h p.i.) p.i.
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direct conjugation of the triazole ring to the phenylurea moi-
ety. Derivatization of the ε-amine of Glu-urea-Lys with a rigid
arm has previously been shown to improve affinity for PSMA
relative to flexible linkers in a series of amide-based PSMA-
targeting fluorescent probes [50] . It is likely that the lack of
conformational flexibility in members of series 2 relative to
Fig. 7 Tumor-to-background ratios of [18F]RPS-040 and [18F]RPS-041 in LNCaP xenograft tumor-bearing mice. a Tumor-to-blood. b Tumor-to-
kidney. c Tumor-to-liver. d Tumor-to-muscle. The large error bars in the tumor/muscle ratio are likely to be due to the low counts recorded in the muscle





injected with 6.66–8.14 MBq
(180–220 μCi) and imaged at 1 h
p.i. a [18F]RPS-040; b [18F]RPS-
041; c [68Ga]Ga-PSMA-HBED-
CC
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members of series 1 contributes to the improvements observed
in binding affinity and tumor uptake.
The second trend emerges from a comparison of the sub-
stitution position on the phenyl ring. Tumor uptake is in the
order 3 > 4 > 2 for both series of compounds (Table 1). This
order of preference was unexpected given previous SAR stud-
ies with a halogenated small molecule PSMA inhibitor, which
indicated a strong preference for substitution at the 4-position
[26], and with (alkoxyphenyl)urea derivatives of Glu-urea-
Lys, for which substitution at the 2-position led to higher-
affinity compounds [51]. It also did not correspond to the rank
order of IC50 values determined in LNCaP cells. Furthermore,
the two compounds substituted at the 2-position, RPS-039 and
RPS-042, showed clearance via the hepatobiliary pathway in
addition to renal excretion, contributing to a lower contrast
tumor image. These trends suggest that substitution at the 2-
position of the phenylurea does not appear to be detrimental to
ligand potency as determined by in vitro assay, but it does
negatively influence the in vivo imaging characteristics of
the tracer.
In spite of the increased tumor uptake of the 3-substituted
[18F]RPS-040 relative to 4-substituted [18F]RPS-041, the
clearance of [18F]RPS-041 is more rapid, leading to greater
image contrast and a higher tumor-to-background ratio at 2 h
p.i. (Figs. 4 and 7). The clearance of [18F]RPS-038, the phenyl
ether analogue of [18F]RPS-041, is similarly more rapid than
[18F]RPS-043 (Fig. 4). It is not apparent based on the μPET/
CT images alone whether the same trend is true for com-
pounds [18F]RPS-043 and [18F]RPS-038, so the significance
of the finding in the context of SAR studies requires further
investigation.
The imaging characteristics of each of the six
[18F]fluorinated triazole PSMA ligands compare favorably
to [68Ga]Ga-PSMA-HBED-CC, the most widely used diag-
nostic PET imaging agent for prostate cancer. In addition to
the greater sensitivity and higher spatial resolution that
Fig. 9 Comparison of uptake in tumor, kidney and blood between [18F]RPS-040, [18F]RPS-041 and [68Ga]Ga-PSMA-HBED-CC. a Tumor-to-blood
ratio at 1 h p.i. and 2 h ([68Ga]Ga-PSMA-HBED-CC) or 3 h p.i. b Tumor-to-kidney ratio. c Tumor uptake
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fluorine-18 offers over gallium-68 [52], the two- to three-fold
higher tumor uptake is evident when images are compared in
the same intensity scale (Fig. 8). The improved image quality
is reinforced by the biodistribution studies with ligands
[18F]RPS-040 and [18F]RPS-041, which showed significantly
greater tumor-to-background and tumor-to-kidney ratios than
[68Ga]Ga-PSMA-HBED-CC (Fig. 9).
[18F]DCFPyL, a second-generation [18F]fluorinated
PSMA ligand currently undergoing clinical evaluation, has
recently been studied in LNCaP tumor xenografts, and the
maximum standardized uptake value (SUVmax ) was reported
to be 1.1 ± 0.1 at 1 h p.i. [25]. This is lower uptake than
observed for each of the six RPS ligands, for which SUV at
1 h p.i. is estimated to range from 1.5 to 2.5 and SUVmax in the
tumor is calculated to range from approximately 1.5 to 2.9.
Moreover, [18F]DCFPyL is reported to have a tumor-to-blood
ratio of 8.3 at 1 h p.i. in LNCaP xenograft tumor-bearing mice
[25]. At this same time point, the tumor-to-blood ratios for
[18F]RPS-040 and [18F]RPS-041 are 28.8 ± 8.06 and 20.78
± 7.87, respectively. By 4 h p.i., the prolonged tumor retention
and rapid blood clearance drives the ratios to 92.93 ± 75.67
and 118.4 ± 69.4, respectively.
[18F]DCFPyL was compared by μPET/CT imaging to the
RPS ligands in the same LNCaP xenograft tumor-bearing
mice. Clearance from the kidneys was rapid, but rapid tumor
washout was also evident (Fig. 4). These pharmacokinetics
contribute to a reduction in signal in the kidneys, but also to
poorer tumor delineation than can be achieved with the RPS
series. The in vitro binding of PSMA-targeting ligands to
mouse kidney cells was reported to be at least two-fold greater
than binding to human kidney cells [53], suggesting that rapid
kidney clearance in pre-clinical mouse models of prostate
cancer is not an essential requirement. In this light, the greater
tumor uptake, longer tumor retention and greater tumor-to-
blood ratios of [18F]RPS-040 and [18F]RPS-041 compared
to [18F]DCFPyL are favorable characteristics of these poten-
tial PET imaging agents.
Our approach to the development of PET-based PSMA
tracers focused on fluorine-18 due its near optimal PET imag-
ing characteristics [54] and the application of the
radiosynthon, [18F]fluoroethylazide, allowed us to achieve
our radiosynthetic goals simply and efficiently. The use of
[18F]fluoroethylazide may add further complexity to automa-
tion when using single-purpose or cassette-based synthesis
units, in use today by many PET centers, due to the need to
label the synthon, purify it by distillation, and carry out the
subsequent click reaction in a single reaction pot. Initial work
has begun on the adaptation of commercially available cas-
settes to facilitate the distillation step. In parallel, an afford-
able, fit-for-purpose custom radiosynthesis box is being de-
veloped. The robust chemical and mechanical reproducibility
of a synthesis box of this type has already been demonstrated
by our group [55].
Conclusions
Six PSMA inhibitors were synthesized and [18F]fluorinated
by a Cu(I) -ca ta lyzed cl ick react ion involving a
2-[18F]fluoroethylazide prosthetic group. Although the radio-
chemistry is currently undergoing optimization, the initial iso-
lation of the [18F]RPS series in 105 min and 20–40 % decay-
corrected yield is a promising starting point for further opti-
mization and automation. Each of the compounds showed
high affinity for PSMA (4–36 nM) in LNCaP cells and good
tumor uptake (>5 %ID/g) in LNCaP xenograft tumor-bearing
mice. The compounds compare favorably to [68Ga]Ga-
PSMA-HBED-CC, a PSMA imaging probe in widespread
c l i n i c a l deve lopmen t , and to [ 1 8F ]DCFPyL , a
[18F]fluorinated PSMA ligand currently under clinical inves-
tigation. Two ligands in particular, [18F]RPS-040 and
[18F]RPS-041, show excellent tumor uptake and retention
(>10 %ID/g) and high tumor-to-background and tumor-to-
kidney ratios. The simple radiosynthesis, promising biological
characteristics and numerous beneficial attributes of fluorine-
18 as a radionuclide for imaging are evidence for the merit of
further clinical development of these ligands as agents for the
imaging of prostate cancer by positron emission tomography.
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